Celiac Science
Argenx's $2.2 Billion Acquisition: What a Vitiligo Deal Means for Celiac Patients
Argenx acquires Forte for $2.2B and its phase 2 vitiligo drug. Here's why this autoimmune deal matters to celiac patients and families.
Argenx acquires Forte for $2.2B and its phase 2 vitiligo drug. Here's why this autoimmune deal matters to celiac patients and families.
New research reveals 44% of patients with dermatitis herpetiformis (celiac disease of the skin) experience neurological issues, highlighting the systemic nature of celiac disease.